Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Congraulations to Professor Ming Lei who has been announced as the recipient of the 2026 Mabel Fitzgerald Prize for Diversity in Physiology, presented by the Physiological Society.

Professor Ming Lei2026 Prize Lecture recipients will be featured at events throughout the Physiological Society’s 150th anniversary celebrations. The Mabel Fitzgerald Prize celebrates excellence in physiological research from scientists from underrepresented backgrounds. Ming’s research has transformed cardiacscience by uncovering new pacemaking mechanisms and therapeutic targets, and leading a global overhaul of antiarrhythmic drug classification. Ming commented, “I am so delighted by this remarkable recognition at occasion of the Physiological Society’s 150 anniversary”, while Fran said “Very many congratulations to Ming on this amazing achievement”.

Similar stories

Modernized Oxford anti-arrhythmic drug classification gains global recognition as the new standard in antiarrhythmic drug clinical guidelines

Cardiac arrhythmias pose a serious global health challenge. The commonest sustained arrhythmia atrial fibrillation (AF) affects 1–2% of the worldwide population. Antiarrhythmic drugs (AADs) remain central to their pharmacotherapeutic management. As a solution, Professors Ming Lei, Derek Terrar (both Pharmacology), Christopher Huang (University of Cambridge), and Lin Wu (Beijing University Hospital) developed and proposed the 2018 Oxford modernized antiarrhythmic drug (AAD) classification (Circulation, 2018;138:1879–1896).